BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

BioAge Labs (NASDAQ: BIOA) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2-4, 2025. Company leaders Kristen Fortney, PhD, CEO, and Dov Goldstein, MD, CFO, will participate in a fireside chat on December 4, 2025 from 1:30–1:55 PM ET and will hold one-on-one meetings.

A live webcast will be available with registration, and replays will be archived in the company investor section at https://ir.bioagelabs.com/ for 30 days after the presentations.

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025.

Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Thursday, December 4 from 1:30 - 1:55 PM ET, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity and cardiovascular risk factors. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

When will BioAge Labs (BIOA) present at the Piper Sandler 37th Annual Healthcare Conference?

BioAge Labs will present during the conference on December 2–4, 2025, with the fireside chat on December 4, 2025 at 1:30–1:55 PM ET.

Who from BioAge Labs (BIOA) will speak at the Piper Sandler conference on December 4, 2025?

Kristen Fortney, PhD, CEO, and Dov Goldstein, MD, CFO, will participate in the fireside chat and one-on-one meetings.

How can investors watch the BioAge Labs (BIOA) presentation live at the Piper Sandler conference?

Investors can access the live webcast by registering as directed in the company announcement; registration is required to view the live stream.

Will the BioAge Labs (BIOA) webcast from the Piper Sandler conference be available after the event?

Yes. Replays will be available in the investor section at https://ir.bioagelabs.com/ and will be archived for 30 days following the presentations.

What time is the BioAge Labs (BIOA) fireside chat at the Piper Sandler conference in New York?

The fireside chat is scheduled for Thursday, December 4, 2025 from 1:30–1:55 PM ET.